I am writing in response to your editorial and article in the August 2006 issue regarding radiation dose concerns ("Soaring CT use may prompt need for long-term dose monitoring," page 5, and "Meetings present strategies for lowering dose loads," page 19). The use of MRI as a replacement for many CT indications would also prove beneficial. In particular, with more rapid body imaging, MR can replace CT of the abdomen and pelvis in regard to the solid organs and hollow viscera. In Europe, for example, imaging of inflammatory bowel disease has recently been outlined in the literature.
The root cause of excessive initial imaging and reimaging needs to be addressed as well. Referring clinicians are being held hostage to medicolegal concerns when ordering endless "rule-out studies." Radiologists often subsequently find an "incidentaloma" that is unlikely to be of clinical significance but is followed with CT surveillance as our litigious society demands.
Finally, the excessive imaging that is necessitated by frivolous lawsuits may lead to a new wave of future class-action claims replacing those related to asbestos and silicone breast implants. I would not be surprised a decade from now to hear the following in a late-night commercial: "Have you ever had a CAT scan? Do you have cancer? Call 1-800-DOCTORSUE. You may be entitled to a large cash settlement from the equipment manufacturers, hospitals, imaging centers, and radiologists who knowingly exposed you to radiation despite the National Toxicology Program classifying x-rays as a known human carcinogen in 2005."
I am pessimistic that lobbying for true tort reform will be effective while the three branches of government are populated by a large number of lawyers. In the meantime, we need to develop national standards to inform our patients about ALARA and educate our referring physicians on American College of Radiology appropriateness criteria.
-Paul S. Needelman M.D.
Great Neck, NY
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.